The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI.

ABSTRACT:

Background

Erythropoietin (Epo) has been shown to improve myocardial function in models of experimental myocardial infarction, but has also been associated with a rise in thromboembolic events. Thus, the aim of this study was to investigate the influence of Epo on platelet activation and coagulation in patients with acute myocardial infarction (AMI).

Methods

The study was designed as a substudy of the randomised, double-blind, placebo controlled REVIVAL-3 (REgeneration of VItal Myocardium in ST-Segment EleVation MyocardiAL Infarction by Erythropoietin) study that investigated the effects of recombinant human Epo in AMI. Serial venous blood samples were collected before and after study medication. Circulating prothrombin fragment F1 + 2, FVII, active FVII, beta thromboglobuli

SUBMITTER: Demetz G 

PROVIDER: S-EPMC4165375 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature